{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-080026","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.968757+00:00","generated_at":"2026-05-31T23:52:02.367417+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Heron Therapeutics announces FDA acceptance of ZYNRELEF VAN supplement; PDUFA goal date September 23, 2024","bullets":["FDA acknowledged receipt of Prior Approval Supplement for ZYNRELEF Vial Access Needle (bupivacaine/meloxicam); PDUFA goal date September 23, 2024.","If approved, VAN would replace vented vial spike, reducing withdrawal time from up to 3 minutes to 20-45 seconds.","VAN expected to be available in Q4 2024 if approved; CrossLink partnership on track to add ~650 representatives by year-end.","CEO Craig Collard expressed optimism that VAN and CrossLink partnership could increase adoption among orthopedic surgeons."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-080026","json":"https://secwatch.observer/filing/0000950170-24-080026.json","markdown":"https://secwatch.observer/filing/0000950170-24-080026.md","text":"https://secwatch.observer/filing/0000950170-24-080026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017024080026/0000950170-24-080026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017024080026/hrtx-20240702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:52:02.367417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}